Collateral effects of the pandemic in oncology patients

Collateral effects of the pandemic in oncology patients - KePoP

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00036023

Enrollment

40000

Registered

2025-08-29

Start date

2026-04-02

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C34 C25 C18

Interventions

Group 1: Patients with tumors of the respiratory tract (ICD-10 C34.-)

Retrospective analysis of routine data from hospitals are used to examine the frequency of diagnostic and/or therapeutic measures in order to investigate the collateral effects of the pandemic. Group

Retrospective analysis of routine data from hospitals are used to examine the frequency of diagnostic and/or therapeutic measures in order to investigate the collateral effects of the pandemic.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: There was contact with a participating healthcare facility in the period from 01.04.2018 to 31.03.2023 and one of the following diagnosis categories: C18, C25 or C34

Exclusion criteria

Exclusion criteria: All data records, that do not match the inclusion criteria

Design outcomes

Primary

Measure	Time frame
(Hospital) mortality rate for the diagnoses “Malignant neoplasm of the bronchi and lung” C34, “Malignant neoplasm of the pancreas” C25 and “Malignant neoplasm of the colon” C18 in the periods before (04.2018-03.2020), during (04.2020-03.2022) and after (04.2022-03.2024) the Covid-19 pandemic	—

Secondary

Measure	Time frame
1. Survey of incidences of diagnoses C34.-, C25.- and C18.- in the periods before, during and after the Covid-19 pandemic 2. Rate of diagnostics performed in the periods before, during and after the Covid-19 pandemic: Computed tomography (CT), magnetic resonance imaging (MRI), biopsy sampling during diagnostic endoscopy, endoscopic sonography, endoscopic retrograde cholangiopancreaticography (ERCP) and selected tumor markers (carcinoembryonic antigen [CEA], carbohydrate antigen 19-9 [CA19-9], neurospecific enolase [NSE]) in the 6 periods before, during and after the Covid-19 pandemic 3. rate of therapeutic procedures in the periods before, during and after the Covid-19 pandemic: lung resection, colon resection and pancreatic surgery, radiotherapy and anti-neoplastic and immunomodulatory drugs in the periods before, during and after the Covid-19 pandemic 4. optional: rate of higher tumor stages in the periods before, during and after the Covid-19 pandemic 5. rate of psychiatric comorbidities (F10.- to F19.-, F20.- to F29.-, F30.- to F39.-, F40.- to F48.-, F50 to F59.-) in the periods before, during and after the Covid-19 pandemic	—

Measure

Time frame

1. Survey of incidences of diagnoses C34.-, C25.- and C18.- in the periods before, during and after the Covid-19 pandemic 2. Rate of diagnostics performed in the periods before, during and after the Covid-19 pandemic: Computed tomography (CT), magnetic resonance imaging (MRI), biopsy sampling during diagnostic endoscopy, endoscopic sonography, endoscopic retrograde cholangiopancreaticography (ERCP) and selected tumor markers (carcinoembryonic antigen [CEA], carbohydrate antigen 19-9 [CA19-9], neurospecific enolase [NSE]) in the 6 periods before, during and after the Covid-19 pandemic 3. rate of therapeutic procedures in the periods before, during and after the Covid-19 pandemic: lung resection, colon resection and pancreatic surgery, radiotherapy and anti-neoplastic and immunomodulatory drugs in the periods before, during and after the Covid-19 pandemic 4. optional: rate of higher tumor stages in the periods before, during and after the Covid-19 pandemic 5. rate of psychiatric comorbidities (F10.- to F19.-, F20.- to F29.-, F30.- to F39.-, F40.- to F48.-, F50 to F59.-) in the periods before, during and after the Covid-19 pandemic

—

Countries

Germany

Contacts

Public ContactAnne-Christin Gude

Ruhr-Universität Bochum, Institut für Diversitätsmedizin

Anne-Christin.Gude@ruhr-uni-bochum.de49 234 3212434

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026